ZA200802897B - New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease - Google Patents
New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's DiseaseInfo
- Publication number
- ZA200802897B ZA200802897B ZA200802897A ZA200802897A ZA200802897B ZA 200802897 B ZA200802897 B ZA 200802897B ZA 200802897 A ZA200802897 A ZA 200802897A ZA 200802897 A ZA200802897 A ZA 200802897A ZA 200802897 B ZA200802897 B ZA 200802897B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrimidine derivatives
- alzheimer
- medicament
- therapy
- disease
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 2
- 150000003230 pyrimidines Chemical class 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502174 | 2005-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200802897B true ZA200802897B (en) | 2008-12-31 |
Family
ID=37906403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200802897A ZA200802897B (en) | 2005-10-03 | 2008-04-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090105252A1 (enExample) |
| EP (1) | EP1945628A4 (enExample) |
| JP (1) | JP2009513575A (enExample) |
| KR (1) | KR20080059423A (enExample) |
| CN (1) | CN101326179A (enExample) |
| AR (1) | AR058073A1 (enExample) |
| AU (2) | AU2006297890B2 (enExample) |
| BR (1) | BRPI0616658A2 (enExample) |
| CA (1) | CA2624875A1 (enExample) |
| EC (1) | ECSP088405A (enExample) |
| IL (1) | IL190150A0 (enExample) |
| NO (1) | NO20082067L (enExample) |
| NZ (2) | NZ566804A (enExample) |
| RU (2) | RU2433128C2 (enExample) |
| SG (1) | SG166125A1 (enExample) |
| TW (1) | TW200800957A (enExample) |
| UA (1) | UA92181C2 (enExample) |
| UY (1) | UY29827A1 (enExample) |
| WO (1) | WO2007040440A1 (enExample) |
| ZA (1) | ZA200802897B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| WO2009017455A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| JP5640005B2 (ja) * | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物 |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| KR20110038159A (ko) | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
| MY154000A (en) * | 2008-09-22 | 2015-04-30 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP2419425A4 (en) * | 2009-04-15 | 2012-08-29 | Astrazeneca Ab | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| ES2463826T3 (es) | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
| CA2763786C (en) | 2009-06-08 | 2014-09-30 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| JP2017524739A (ja) | 2014-07-17 | 2017-08-31 | アンセルムＩｎｓｅｒｍ | 神経筋接合部関連疾患の処置方法 |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| CA3172750A1 (en) * | 2020-03-23 | 2021-09-30 | Ge Hyeong Lee | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
| KR102342803B1 (ko) * | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| TW202227401A (zh) * | 2020-10-23 | 2022-07-16 | 大陸商重慶兩江藥物研發中心有限公司 | 用於持續釋放治療劑的前藥及其用途 |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| WO2022232259A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530710A1 (de) | 1985-08-28 | 1987-03-05 | Hoechst Ag | Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| BR0207096A (pt) * | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| IL161662A0 (en) * | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors) |
| WO2003076434A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| CA2515132C (en) * | 2003-02-07 | 2012-01-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| US7456190B2 (en) * | 2003-03-13 | 2008-11-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US7132651B2 (en) | 2004-04-23 | 2006-11-07 | Framatome Anp, Inc. | In-situ BWR and PWR CRUD flake analysis method and tool |
| BRPI0614502A2 (pt) * | 2005-07-30 | 2011-03-29 | Astrazeneca Ab | Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| EP2419425A4 (en) * | 2009-04-15 | 2012-08-29 | Astrazeneca Ab | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE |
-
2006
- 2006-09-29 UY UY29827A patent/UY29827A1/es not_active Application Discontinuation
- 2006-09-29 AR ARP060104310A patent/AR058073A1/es not_active Application Discontinuation
- 2006-10-02 CN CNA2006800454648A patent/CN101326179A/zh active Pending
- 2006-10-02 US US12/089,008 patent/US20090105252A1/en not_active Abandoned
- 2006-10-02 SG SG201007265-0A patent/SG166125A1/en unknown
- 2006-10-02 RU RU2008110910/04A patent/RU2433128C2/ru not_active IP Right Cessation
- 2006-10-02 AU AU2006297890A patent/AU2006297890B2/en not_active Ceased
- 2006-10-02 JP JP2008534486A patent/JP2009513575A/ja active Pending
- 2006-10-02 WO PCT/SE2006/001116 patent/WO2007040440A1/en not_active Ceased
- 2006-10-02 CA CA002624875A patent/CA2624875A1/en not_active Abandoned
- 2006-10-02 EP EP06799716A patent/EP1945628A4/en not_active Withdrawn
- 2006-10-02 NZ NZ566804A patent/NZ566804A/en not_active IP Right Cessation
- 2006-10-02 UA UAA200802783A patent/UA92181C2/ru unknown
- 2006-10-02 BR BRPI0616658-0A patent/BRPI0616658A2/pt not_active IP Right Cessation
- 2006-10-02 KR KR1020087010755A patent/KR20080059423A/ko not_active Ceased
- 2006-10-02 NZ NZ591316A patent/NZ591316A/en not_active IP Right Cessation
- 2006-10-03 TW TW095136796A patent/TW200800957A/zh unknown
-
2008
- 2008-03-13 IL IL190150A patent/IL190150A0/en not_active IP Right Cessation
- 2008-04-02 ZA ZA200802897A patent/ZA200802897B/xx unknown
- 2008-04-28 EC EC2008008405A patent/ECSP088405A/es unknown
- 2008-04-30 NO NO20082067A patent/NO20082067L/no not_active Application Discontinuation
-
2011
- 2011-03-03 AU AU2011200948A patent/AU2011200948A1/en not_active Abandoned
- 2011-04-20 RU RU2011115406/04A patent/RU2011115406A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2433128C2 (ru) | 2011-11-10 |
| EP1945628A1 (en) | 2008-07-23 |
| AR058073A1 (es) | 2008-01-23 |
| UA92181C2 (ru) | 2010-10-11 |
| AU2006297890B2 (en) | 2011-04-28 |
| EP1945628A4 (en) | 2010-06-02 |
| RU2011115406A (ru) | 2012-10-27 |
| AU2011200948A1 (en) | 2011-03-24 |
| NZ566804A (en) | 2011-03-31 |
| AU2006297890A1 (en) | 2007-04-12 |
| US20090105252A1 (en) | 2009-04-23 |
| UY29827A1 (es) | 2007-05-31 |
| CN101326179A (zh) | 2008-12-17 |
| RU2008110910A (ru) | 2009-11-10 |
| IL190150A0 (en) | 2008-08-07 |
| WO2007040440A1 (en) | 2007-04-12 |
| BRPI0616658A2 (pt) | 2011-06-28 |
| TW200800957A (en) | 2008-01-01 |
| NO20082067L (no) | 2008-07-02 |
| NZ591316A (en) | 2012-06-29 |
| JP2009513575A (ja) | 2009-04-02 |
| ECSP088405A (es) | 2008-05-30 |
| CA2624875A1 (en) | 2007-04-12 |
| KR20080059423A (ko) | 2008-06-27 |
| SG166125A1 (en) | 2010-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190150A0 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease | |
| TWI340640B (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
| ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
| ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
| IL191311A (en) | Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury | |
| HRP20130602T1 (en) | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases | |
| WO2007012061A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| IL190284A (en) | Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia | |
| PT2083837E (pt) | Utilização terapêutica de pelo menos uma neurotoxina botulínica no tratamento da dor induzida por, pelo menos, um agente anti-cancerígeno | |
| EP1940373B8 (en) | 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease | |
| PL1611091T3 (pl) | Podstawione pochodne kwasów fenyloalkanowych i ich zastosowanie do leczenia chorób układu oddechowego | |
| TWI372056B (en) | Novel medicament combinations for the treatment of respiratory diseases | |
| IL185300A0 (en) | New pharmaceutical compositions useful in the treatment of parkinson's disease | |
| IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
| GB0410399D0 (en) | The treatment of respiratory disease | |
| TWI369210B (en) | Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies | |
| IL178815A0 (en) | The treatment of respiratory disease | |
| PL1670482T5 (pl) | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego | |
| IL186022A0 (en) | Dermatological compositions and salts for the treatment of dermatological diseases | |
| ZA200607531B (en) | Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient | |
| AU2003238046A1 (en) | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease | |
| PL2340872T3 (pl) | Nowe preparaty farmaceutyczne użyteczne w leczeniu bezsenności | |
| HK1120037A (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease | |
| HK1119947A (zh) | 嘧啶衍生物在制造用於防止和/或治疗阿兹海默氏症的药物中的用途 | |
| GB0425633D0 (en) | Topical formulations for use in the treatment or prevention of dermatological conditions |